Security Snapshot

UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD) Institutional Ownership

CUSIP: 917488108

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

119

Shares (Excl. Options)

2,266,199

Price

$61.99

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Shares
Symbol
UTMD on Nasdaq
Shares outstanding
3,189,220
Price per share
$68.37
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
2,266,199
Total reported value
$140,491,697
% of total 13F portfolios
0%
Share change
+165,908
Value change
+$10,514,177
Number of holders
119
Price from insider filings
$68.37
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • UTMD - UTAH MEDICAL PRODUCTS INC - Common Shares is tracked under CUSIP 917488108.
  • 119 institutions reported positions in Q1 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 117 to 119 between Q4 2025 and Q1 2026.
  • Reported value moved from $117,525,511 to $140,491,697.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 119 institutions filings for Q1 2026.

Open SEC Evidence

Security key

917488108

Latest holder period

Q1 2026

13F holders

119

13D/G owners

5

CIK / CUSIP context first

Open Q1 2026 holders UTMD full holder history UTAH MEDICAL PRODUCTS INC SEC filings UTAH MEDICAL PRODUCTS INC company facts UTAH MEDICAL PRODUCTS INC insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BRANDES INVESTMENT PARTNERS, LP 14% +37% $27,875,663 +$7,220,347 449,680 +35% BRANDES INVESTMENT PARTNERS, LP 31 Mar 2026
RENAISSANCE TECHNOLOGIES LLC 6.7% $12,107,235 230,614 Renaissance Technologies LLC 30 Sep 2024
DIMENSIONAL FUND ADVISORS LP 6.1% $11,239,863 197,466 Dimensional Fund Advisors LP 30 Jun 2025
BlackRock, Inc. 5.3% +6.6% $9,829,260 +$231,666 172,684 +2.4% BlackRock, Inc. 30 Jun 2025
FMR LLC 2.7% $4,848,900 92,360 FMR LLC 31 Dec 2024

As of 31 Mar 2026, 119 institutional investors reported holding 2,266,199 shares of UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD). This represents 71% of the company’s total 3,189,220 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD) together control 63% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BRANDES INVESTMENT PARTNERS, LP 14% 449,279 +28% 0.2% $27,850,805
DIMENSIONAL FUND ADVISORS LP 6.2% 197,908 +0.71% 0% $12,269,266
BlackRock, Inc. 5.9% 187,649 +1.7% 0% $11,632,375
RENAISSANCE TECHNOLOGIES LLC 5.8% 184,114 -4.9% 0.02% $11,413,227
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 138,560 0% 0% $8,589,334
GEODE CAPITAL MANAGEMENT, LLC 3.8% 120,097 +37% 0% $7,446,218
Minerva Advisors LLC 2.9% 93,615 0% 3.7% $5,803,194
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC 2.8% 89,131 -18% 0.02% $5,525,231
RICE HALL JAMES & ASSOCIATES, LLC 2.1% 67,882 +5.4% 0.23% $4,208,005
STATE STREET CORP 2% 64,402 -5.3% 0% $4,012,910
MORGAN STANLEY 1.5% 48,800 +12% 0% $3,025,167
UBS Group AG 1.2% 36,916 +11657% 0% $2,288,423
Huber Capital Management LLC 1.1% 35,915 -2.5% 0.34% $2,226,371
Bank of New York Mellon Corp 1% 32,082 -9.7% 0% $1,988,733
NORTHERN TRUST CORP 0.95% 30,292 +3.5% 0% $1,877,801
Quantinno Capital Management LP 0.94% 29,841 +26% 0% $1,849,870
Cardinal Capital Management 0.83% 26,543 +6.9% 0.21% $1,653,629
EVERETT HARRIS & CO /CA/ 0.8% 25,564 +20% 0.02% $1,584,712
SEGALL BRYANT & HAMILL, LLC 0.68% 21,547 +88% 0.02% $1,335,699
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 0.67% 21,287 +43% 0.01% $1,319,581
LSV ASSET MANAGEMENT 0.62% 19,859 +47% 0% $1,231,000
VANGUARD FIDUCIARY TRUST CO 0.6% 19,056 0% 0% $1,181,281
BARD ASSOCIATES INC 0.58% 18,361 +0.88% 0.29% $1,143,866
PRICE T ROWE ASSOCIATES INC /MD/ 0.57% 18,300 +25% 0% $1,135,000
FMR LLC 0.57% 18,062 +36% 0% $1,119,664

Institutional Holders of UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 2,266,199 $140,491,697 +$10,514,177 $61.99 119
2025 Q4 2,099,545 $117,525,511 -$3,861,909 $55.96 117
2025 Q3 2,166,272 $136,441,085 +$654,850 $62.97 115
2025 Q2 2,154,610 $122,645,130 -$4,286,491 $56.92 109
2025 Q1 2,232,321 $125,139,291 -$4,053,654 $56.04 107
2024 Q4 2,305,146 $141,733,881 -$6,984,040 $61.47 112
2024 Q3 2,408,468 $161,160,273 +$1,503,694 $66.91 109
2024 Q2 2,402,050 $160,517,663 -$6,987,298 $66.81 99
2024 Q1 2,489,842 $177,079,892 -$5,994,623 $71.11 99
2023 Q4 2,515,087 $211,858,896 -$5,241,769 $84.22 88
2023 Q3 2,572,783 $221,288,021 +$1,886,299 $86.00 91
2023 Q2 2,546,722 $237,462,990 +$487,123 $93.20 89
2023 Q1 2,542,875 $241,013,763 +$8,482,645 $94.77 86
2022 Q4 2,546,245 $255,980,665 +$1,190,438 $100.53 81
2022 Q3 2,535,532 $216,324,656 -$31,278,340 $85.31 75
2022 Q2 2,559,522 $219,885,103 -$450,030 $85.90 74
2022 Q1 2,572,731 $231,180,696 -$2,805,351 $89.86 84
2021 Q4 2,603,370 $260,419,500 -$912,880 $100.00 78
2021 Q3 2,601,860 $241,516,691 +$243,574 $92.83 72
2021 Q2 2,599,575 $221,087,106 -$2,811,784 $85.04 68
2021 Q1 2,632,036 $227,952,680 +$1,009,922 $86.60 78
2020 Q4 2,620,725 $220,943,842 -$2,326,872 $84.30 76
2020 Q3 2,651,007 $211,813,071 -$2,768,168 $79.87 83
2020 Q2 2,681,470 $237,657,730 +$3,950,332 $88.62 91
2020 Q1 2,628,004 $247,165,094 -$14,110,945 $94.05 89
2019 Q4 2,771,884 $299,105,893 -$7,842,685 $107.90 95
2019 Q3 2,845,261 $272,705,817 +$14,362,424 $95.84 94
2019 Q2 2,695,866 $257,857,946 +$3,901,787 $95.70 96
2019 Q1 2,667,666 $235,422,594 -$153,905 $88.25 90
2018 Q4 2,678,889 $222,557,936 -$9,708,244 $83.08 85
2018 Q3 2,788,384 $262,649,786 +$18,705,556 $94.20 89
2018 Q2 2,586,431 $284,806,927 +$1,054,670 $110.15 91
2018 Q1 2,585,740 $255,600,294 +$9,117,799 $98.85 78
2017 Q4 2,497,435 $203,092,527 +$2,126,789 $81.40 78
2017 Q3 2,480,589 $182,487,296 +$233,743 $73.55 74
2017 Q2 2,477,645 $179,356,830 +$4,870,819 $72.40 75
2017 Q1 2,421,128 $150,830,508 +$6,332,169 $62.30 76
2016 Q4 2,477,886 $180,211,111 -$462,985 $72.75 75
2016 Q3 2,500,148 $149,501,799 -$1,271,482 $59.80 78
2016 Q2 2,519,897 $158,750,245 -$2,050,779 $63.00 76
2016 Q1 2,555,094 $159,803,564 +$3,079,935 $62.54 68
2015 Q4 2,531,311 $148,131,615 +$2,531,634 $58.54 65
2015 Q3 2,466,259 $133,025,937 -$477,134 $53.87 58
2015 Q2 2,473,912 $147,468,790 +$3,581,938 $59.63 63
2015 Q1 2,413,527 $144,447,777 -$3,605,115 $59.86 59
2014 Q4 2,473,676 $148,510,172 -$16,219 $60.05 60
2014 Q3 2,205,551 $107,547,653 -$11,678,366 $48.76 60
2014 Q2 2,427,382 $124,860,931 +$1,473,685 $51.44 60
2014 Q1 2,397,038 $138,529,175 +$3,536,633 $57.83 58
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .